je.st
news
Tag: alkermes
Reset Therapeutics, Inc. Establishes Research Collaboration With Alkermes For Discovery And Development Of Novel Orexin Modulators
2016-03-30 06:05:57| drugdiscoveryonline Home Page
Reset Therapeutics, Inc., announced recently a collaboration with an affiliate of Alkermes plc for the discovery, development and commercialization of novel orexin receptor modulators from Reset’s drug discovery platform
Tags: research
development
novel
collaboration
AvalonBay Communities, Equinix, Jarden, Alkermes Approach 52-Week Highs
2016-01-05 06:29:00| Appliances - Topix.net
According to GuruFocus list of 52-week highs ; AvalonBay Communities Inc., Equinix Inc., Jarden Corp. and Alkermes PLC have all reached their yearly highs. AvalonBay Communities has a market cap of $25.2 billion, and its shares were traded at around $184.13 per share with a P/E ratio of 33.70 and a P/S ratio of 13.53.
Tags: approach
communities
highs
avalonbay
Alkermes Announces Achievement Of Milestones For CNS Medicines In Proprietary Product And Pipeline Portfolio
2015-12-21 04:02:36| dairynetwork News Articles
Alkermes plc recentlyannounced new developments and milestones related to its proprietary product and late-stage pipeline portfolio of medicines for the treatment of central nervous system (CNS) diseases
Tags: product
portfolio
achievement
announces
Alkermes: Sale of 'non-core' CMO unit supports blossoming portfolio
2015-05-05 09:53:59| Biotech - Topix.net
Alkermes will continue to streamline its manufacturing and infrastructure to support a growing portfolio following the sale of its legacy CMO site. The sale of Alkermes' contract manufacturing facility in Gainesville, Georgia, to Recro Pharma was completed last month netting the pharma firm $50m and future royalties on meloxicam IV/IM.
Tags: sale
unit
supports
portfolio
Alkermes says trial results of reformulated Tecfidera show fewer side effects
2015-02-09 15:30:42| Biotech - Topix.net
Irish drug company Alkermes says results of an early-stage trial of its reformulated version of Biogen Idec's blockbuster multiple sclerosis pill show it may have fewer side effects, and has potential to be taken once a day instead of twice. Alkermes , which has a significant research facility in Waltham, said the Phase 1 trial of 104 healthy people compared its reformulation of the active ingredient in Tecfidera, which it calls ALKS 8700, to both the original and a placebo.
Tags: show
results
side
effects